<DOC>
	<DOC>NCT02253849</DOC>
	<brief_summary>Study to assess the steady-state pharmacokinetics of carbamazepine (CBZ) at 200 mg or 100 mg twice daily, depending on tolerability, and administered alone and in combination with tipranavir/ritonavir (TPV/r) after a single dose (500/200 mg) and at steady-state (500/200 mg twice-daily)</brief_summary>
	<brief_title>Effects of TPV/r on the Pharmacokinetics of Carbamazepine in Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Healthy male and nonpregnant, nonlactating female subjects as determined by results of screening Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements Age &gt;19 and &lt;59 years Weight ≥ 60 kg BMI &gt;18.5 and &lt;35 kg/m2 Ability to maintain adequate contraception if applicable Any finding of the medical examination (including blood pressure, pulse rate, and electrocardiogram) deviating from normal and of clinical relevance AV block including 1° Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, haematological, oncological or hormonal disorders Surgery of gastrointestinal tract (except appendectomy) Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders Relevant history of orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator Known hypersensitivity to TPV, Ritonavir (RTV), carbamazepine or antiretroviral drugs (marketed or experimental use as part of clinical research studies) Known elevated liver enzymes in past trials with any compound Intake of drugs with a long halflife (&gt;24 hours) (&lt;1 month prior to administration or during the trial) Prescription or over the counter medications (including vitamins, minerals, herbal supplements and antacids), dietary supplements 14 days prior to study drug administration or expected during the trial) Participation in another trial with an investigational drug (&lt;2 months prior to administration or expected during trial) Smoker with a consumption of &gt;10 cigarettes or &gt;3 cigars or &gt;3 pipes/day and those who cannot keep tobacco intake constant Alcohol abuse (&gt;60 g/day) Drug abuse Blood donation or loss &gt;400 mL, &lt;1 month prior to administration or expected during the trial Clinically relevant laboratory abnormalities Inability to comply with dietary regimen of study centre For female subjects: Pregnancy or planning to become pregnant within 60 days of study completion Positive pregnancy test Have not been using a barrier method of contraception for at least 3 months prior to participation in the study Are not willing or are unable to use a reliable method of barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during and up to 2 months after completion/termination of the trial Chronic use of oral contraception or hormone replacement containing ethinyl estradiol Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>58 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>